Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer
JF Gainor, AT Shaw - Journal of clinical oncology, 2013 - ascopubs.org
The success of tyrosine kinase inhibitors (TKIs) in select patients with non–small-cell lung
cancer (NSCLC) has transformed management of the disease, placing new emphasis on …
cancer (NSCLC) has transformed management of the disease, placing new emphasis on …
[HTML][HTML] The pivotal role of pathology in the management of lung cancer
MR Davidson, AF Gazdar, BE Clarke - Journal of thoracic disease, 2013 - ncbi.nlm.nih.gov
The last decade has seen significant advances in our understanding of lung cancer biology
and management. Identification of key driver events in lung carcinogenesis has contributed …
and management. Identification of key driver events in lung carcinogenesis has contributed …
[HTML][HTML] Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American …
NI Lindeman, PT Cagle, MB Beasley, DA Chitale… - Journal of Thoracic …, 2013 - Elsevier
Objective To establish evidence-based recommendations for the molecular analysis of lung
cancers that are that are required to guide EGFR-and ALK-directed therapies, addressing …
cancers that are that are required to guide EGFR-and ALK-directed therapies, addressing …
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
DR Camidge, YJ Bang, EL Kwak, AJ Iafrate… - The lancet …, 2012 - thelancet.com
Background ALK fusion genes occur in a subset of non-small-cell lung cancers (NSCLCs).
We assessed the tolerability and activity of crizotinib in patients with NSCLC who were …
We assessed the tolerability and activity of crizotinib in patients with NSCLC who were …
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
RC Doebele, AB Pilling, DL Aisner, TG Kutateladze… - Clinical cancer …, 2012 - AACR
Purpose: Patients with anaplastic lymphoma kinase (ALK) gene rearrangements often
manifest dramatic responses to crizotinib, a small-molecule ALK inhibitor. Unfortunately, not …
manifest dramatic responses to crizotinib, a small-molecule ALK inhibitor. Unfortunately, not …
ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer
Purpose: Anaplastic lymphoma kinase (ALK) gene rearrangements define a distinct
molecular subset of non–small cell lung cancer (NSCLC). Recently, several case reports …
molecular subset of non–small cell lung cancer (NSCLC). Recently, several case reports …
Non–small cell lung cancer, version 6.2015
These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for
Non–Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in …
Non–Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in …
Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer
KD Davies, AT Le, MF Theodoro, MC Skokan… - Clinical Cancer …, 2012 - AACR
Purpose: Oncogenic gene fusions involving the 3′ region of ROS1 kinase have been
identified in various human cancers. In this study, we sought to characterize ROS1 fusion …
identified in various human cancers. In this study, we sought to characterize ROS1 fusion …
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer
G Hrustanovic, V Olivas, E Pazarentzos, A Tulpule… - Nature medicine, 2015 - nature.com
One strategy for combating cancer-drug resistance is to deploy rational polytherapy up front
that suppresses the survival and emergence of resistant tumor cells. Here we demonstrate in …
that suppresses the survival and emergence of resistant tumor cells. Here we demonstrate in …
[HTML][HTML] Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The Second …
consensus conferences to focus on specific issues in each type of tumour. The Second …